Vai al contenuto principale della pagina

Resistance to Ibritumomab in Lymphoma / / edited by Makoto Hosono, Jean-François Chatal



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Titolo: Resistance to Ibritumomab in Lymphoma / / edited by Makoto Hosono, Jean-François Chatal Visualizza cluster
Pubblicazione: Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018
Edizione: 1st ed. 2018.
Descrizione fisica: 1 online resource (161 pages) : illustrations
Disciplina: 616.99446
Soggetto topico: Cancer research
Cancer Research
Persona (resp. second.): HosonoMakoto
ChatalJean-François
Nota di contenuto: Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.
Sommario/riassunto: This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.
Titolo autorizzato: Resistance to Ibritumomab in Lymphoma  Visualizza cluster
ISBN: 3-319-78238-X
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910298421103321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Serie: Resistance to Targeted Anti-Cancer Therapeutics, . 2196-5501 ; ; 18